Vien Sot ret Ky Sinh Trung - Con trung Quy Nhon

Trong bối cảnh nhiều bệnh truyền nhiễm đang nổi và tái nổi, kể cả bệnh ký trùng lây truyền từ động vật sang người đang tiếp tục gia tăng tại nhiều châu lục trên toàn cầu, trong đó đáng quan tâm là nhóm bệnh sán dây vẫn tiếp tục là vấn đề y tế công cộng đáng quan tâm.

Việc phòng chống và loại trừ nó có lẽ phải cần tiếp cận mô hình Một Sức khỏe (One Health Model Approach) mới có thể giảm và tiến tới loại trừ hiệu quả trên toàn cầu và tại Việt Nam.

Hình 1. Các nang sán trên hệ thần kinh và trong cơ

Hình 2. Chu kỳ phát sinh học và phát triển của sán dây và ấu trùng sán dây lợn

Hình 3. Nang sán tiến triển ở các giai đoạn khác nhau trong nhu mô não

Hình 4. Tiến triển nang sán trong nhu mô não và bệnh sinh miễn dịch liên quan

Hình 5. Key cellular and humoral effectors associated with parenchymal and extraparenchymal NCC.

Hình 6. Một số thương tổn do ấu trùng sán dây lợn trên hệ thần kinh

Dưới đây là các tài liệu cập nhật về nghiên cứu bao quát các khía cạnh dịch tễ, lâm sàng, chẩn đoán, điều trị và quản lý ca bệnh, phòng bệnh trên thế giới đang làm.

1. Garcia HH, Del Brutto OH. Taenia solium cysticercosis. Infect Dis Clin North Am. 2000;14:97–119. [PubMed] [Google Scholar]

2. White AC., Jr. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu Rev Med. 2000;51:187–206. [PubMed] [Google Scholar]

3. Commission on Tropical Diseases of the International League Against Epilepsy Relationship between epilepsy and tropical diseases. Epilepsia. 1994;35:89–93. [PubMed] [Google Scholar]

4. Schantz PM, Wilkins PP, Tsang VCW. Immigrants, imaging and immunoblots: the emergence of neurocysticercosis as a significant public health problem. In: Scheld WM, Craig WA, Hughes JM, editors. Emerging infections 2. ASM Press; Washington: 1998. pp. 213–41. [Google Scholar]

5. Henneberg R. Die tierischen parasiten des zentralnervensystem. In: Lewandowsky M, editor. Handbuch der neurologie. Springer; Berlin: 1912. pp. 642–83. [Google Scholar]

6. Flisser A. Taeniasis and cysticercosis due to T solium. In: Sun T, editor. Progress in clinical parasitology. CRC Press; New York: 1994. pp. 77–116. [PubMed] [Google Scholar]

7. Merchant MT, Aguilar L, Avila G, Robert L, Flisser A, Willms K. Taenia solium: description of the intestinal implantation sites in experimental hamster infections. J Parasitol. 1998;84:681–85. [PubMed] [Google Scholar]

8. Pawlowski Z, Schultz MG. Taeniasis and cysticercosis (Taenia saginata) Adv Parasitol. 1972;10:269–343. [PubMed] [Google Scholar]

9. Dixon HB, Lipscomb FM. Cysticercosis: an analysis and follow-up of 450 cases. Medical Research Council; London: 1961. [Google Scholar]

10. Gilman RH, Del Brutto OH, Garcia HH, Martinez M. Prevalence of taeniosis among patients with neurocysticercosis is related to severity of infection. Neurology. 2000;55:1062. [PubMed] [Google Scholar]

11. Garcia HH, Del Brutto OH. Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. Neurology. 1999;53:1582–84. [PubMed] [Google Scholar]

12. Gemmell M, Matyas Z, Pawlowsky Z, Soulsby EJL. Guidelines for surveillance and control of Taeniasis/Cysticercosis. World Health Organization; Geneva: 1983. [Google Scholar]

13. Richards F, Jr, Schantz PM. Cysticercosis and taeniasis. N Engl J Med. 1985;312:787–88. [PubMed] [Google Scholar]

14. Allan JC, Velasquez-Tohom M, Garcia-Noval J, et al. Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities. Ann Trop Med Parasitol. 1996;90:157–65. [PubMed] [Google Scholar]

15. Allan JC, Velasquez-Tohom M, Torres-Alvarez R, Yurrita P, Garcia-Noval J. Field trial of the coproantigen-based diagnosis of Taenia solium taeniasis by enzyme-linked immunosorbent assay. Am J Trop Med Hyg. 1996;54:352–56. [PubMed] [Google Scholar]

16. Garcia HH, Gilman RH, Gonzalez AE, et al. Hyperendemic human and porcine Taenia solium infection in Peru. Am J Trop Med Hyg. 2003;68:268–75. [PubMed] [Google Scholar]

17. Mayta H, Talley A, Gilman RH, et al. Differentiating Taenia solium and Taenia saginata infections by simple hematoxylin-eosin staining and PCR-restriction enzyme analysis. J Clin Microbiol. 2000;38:133–37. [PMC free article] [PubMed] [Google Scholar]

18. Hall A, Latham MC, Crompton DW, Stephenson LS. Taenia saginata (Cestoda) in western Kenya: the reliability of faecal examinations in diagnosis. Parasitology. 1981;83:91–101. [PubMed] [Google Scholar]

19. Garcia HH, Gilman RH, Horton J, et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Neurology. 1997;48:1421–27. [PubMed] [Google Scholar]

20. Allan JC, Avila G, Garcia Noval J, Flisser A, Craig PS. Immunodiagnosis of taeniasis by coproantigen detection. Parasitology. 1990;101:473–77. [PubMed] [Google Scholar]

21. Gonzalez LM, Montero E, Harrison LJ, Parkhouse RM, Garate T. Differential diagnosis of Taenia saginata and Taenia solium infection by PCR. J Clin Microbiol. 2000;38:737–44. [PMC free article] [PubMed] [Google Scholar]

22. Wilkins PP, Allan JC, Verastegui M, et al. Development of a serologic assay to detect Taenia solium taeniasis. Am J Trop Med Hyg. 1999;60:199–204. [PubMed] [Google Scholar]

23. Pearson RD, Hewlett EL. Niclosamide therapy for tapeworm infections. Ann Intern Med. 1985;102:550–51. [PubMed] [Google Scholar]

24. Flisser A, Madrazo I, Plancarte A, et al. Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel. Lancet. 1993;342:748. [PubMed] [Google Scholar]

25. Garcia HH, Araoz R, Gilman RH, et al. Increased prevalence of cysticercosis and taeniasis among professional fried pork vendors and the general population of a village in the Peruvian highlands. Am J Trop Med Hyg. 1998;59:902–05. [PubMed] [Google Scholar]

26. Schantz PM, Moore AC, Munoz JL, et al. Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med. 1992;327:692–95. [PubMed] [Google Scholar]

27. Martinez MJ, De Aluja AS, Gemmell M. Failure to incriminate domestic flies (Diptera: Muscidae) as mechanical vectors of Taenia eggs (Cyclophyllidea: Taeniidae) in rural Mexico. J Med Entomol. 2000;37:489–91. [PubMed] [Google Scholar]

28. Nash TE, Neva FA. Recent advances in the diagnosis and treatment of cerebral cysticercosis. N Engl J Med. 1984;311:1492–96. [PubMed] [Google Scholar]

29. Yoshino K. Studies on the post-embryonal development of Taenia solium: III on the development of Cysticercus cellulosae within the definitive intermediate host. J Med Assoc Formosa. 1933;32:166–69. [Google Scholar]

30. Dixon HBF, Smithers DW. Epilepsy in cysticercosis (Taenia solium): a study of seventy-one cases. QJM. 1934;3:603–16. [Google Scholar]

31. Sahai K, Kapila K, Verma K. Parasites in fine needle breast aspirates—assessment of host tissue response. Postgrad Med J. 2002;78:165–67. [PMC free article] [PubMed] [Google Scholar]

32. Rabiela MT, Rivas A, Rodriguez J, Castillo S, Cancino FM. Anatomopathological aspects of human brain cysticercosis. In: Flisser A, Willms K, Laclette JP, Larralde C, Ridaura C, Beltran F, editors. Cysticercosis: present state of knowledge and perspectives. Academic Press; New York: 1982. pp. 179–200. [Google Scholar]

33. Rahalkar MD, Shetty DD, Kelkar AB, Kelkar AA, Kinare AS, Ambardekar ST. The many faces of cysticercosis. Clin Radiol. 2000;55:668–74. [PubMed] [Google Scholar]

34. Cardenas F, Quiroz H, Plancarte A, Meza A, Dalma A, Flisser A. Taenia solium ocular cysticercosis: findings in 30 cases. Ann Ophthalmol. 1992;24:25–28. [PubMed] [Google Scholar]

35. Wadia N, Desai S, Bhatt M. Disseminated cysticercosis: new observations, including CT scan findings and experience with treatment by praziquantel. Brain. 1988;111:597–614. [PubMed] [Google Scholar]

36. Chandra S, Vashisht S, Menon V, Berry M, Mukherji SK. Optic nerve cysticercosis: imaging findings. AJNR Am J Neuroradiol. 2000;21:198–200. [PMC free article] [PubMed] [Google Scholar]

37. Chang GY, Keane JR. Visual loss in cysticercosis: analysis of 23 patients. Neurology. 2001;57:545–48. [PubMed] [Google Scholar]

38. Evans CAW, Cysticercosis Working Group in Peru . The immunology of the host-parasite relationship in Taenia solium cysticercosis: implications for prevention and therapy. In: Garcia HH, Martinez SM, editors. Taenia solium taeniasis/cysticercosis. 2nd edn. Ed Universo; Lima: 1999. pp. 25–37. [Google Scholar]

39. Carpio A. Neurocysticercosis: an update. Lancet Infect Dis. 2002;2:751–62. [PubMed] [Google Scholar]

40. McArthur WP. Cysticercosis as seen in the British army with special reference to the production of epilepsy. Trans R Soc Trop Med Hyg. 1934;27:343–63. [Google Scholar]

41. Dixon HBF, Hargreaves WH. Cysticercosis (Taenia solium): a further ten years’ clinical study, covering 284 cases. QJM. 1944;13:107–21. [Google Scholar]

42. Chopra JS, Kaur U, Mahajan RC. Cysticerciasis and epilepsy: a clinical and serological study. Trans R Soc Trop Med Hyg. 1981;75:518–20. [PubMed] [Google Scholar]

43. Del Brutto OH, Santibanez R, Noboa CA, Aguirre R, Diaz E, Alarcon TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. 1992;42:389–92. [PubMed] [Google Scholar]

44. Garcia HH, Martinez M, Gilman R, et al. Diagnosis of cysticercosis in endemic regions. Lancet. 1991;338:549–51. [PMC free article] [PubMed] [Google Scholar]

45. Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology. 2002;59:1730–34. [PubMed] [Google Scholar]

46. Lobato RD, Lamas E, Portillo JM, et al. Hydrocephalus in cerebral cysticercosis: pathogenic and therapeutic considerations. J Neurosurg. 1981;55:786–93. [PubMed] [Google Scholar]

47. Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms: a study of 753 cases. Arch Intern Med. 1985;145:442–45. [PubMed] [Google Scholar]

48. Del Brutto OH, Sotelo J, Aguirre R, Diaz-Calderon E, Alarcon TA. Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol. 1992;49:535–38. [PubMed] [Google Scholar]

49. Proano JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001;345:879–85. [PubMed] [Google Scholar]

50. Barrinagarrementeria F, Cantu C. Cerebrovascular manifestations of neurocysticercosis. In: Singh G, Prabhakar S, editors. Taenia solium cysticercosis: from basic to clinical science. CABI Publishing; Oxfordshire: 2002. pp. 221–28. [Google Scholar]

51. Rangel R, Torres B, Del Bruto O, Sotelo J. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg. 1987;36:387–92. [PubMed] [Google Scholar]

52. Parmar H, Shah J, Patwardhan V, et al. MR imaging in intramedullary cysticercosis. Neuroradiology. 2001;43:961–67. [PubMed] [Google Scholar]

53. Trelles JO, Rocca ED, Ravens R. Estudios sobre neurocisticercosis: I sobre la fina estructura de la membrana vesicular quística y racemosa, deducciones patológicas. Rev Neuropsiquiatr (Perú) 1952;15:1–35. [Google Scholar]

54. Escobar A. The pathology of neurocysticercosis. In: Palacios E, Rodriguez-Carbajal J, Taveras JM, editors. Cysticercosis of the central nervous system. Charles C Thomas; Springfield: 1983. pp. 27–54. [Google Scholar]

55. Kramer J, Carrazana EJ, Cosgrove GR, Kleefield J, Edelman RR. Transaqueductal migration of a neurocysticercus cyst: case report. J Neurosurg. 1992;77:956–58. [PubMed] [Google Scholar]

56. Neal JH. An endoscopic approach to cysticercosis cysts of the posterior third ventricle. Neurosurgery. 1995;36:1040–43. [PubMed] [Google Scholar]

57. Zee CS, Go JL, Kim PE, DiGiorgio CM. Imaging of neurocysticercosis. Neuroimaging Clin N Am. 2000;10:391–407. [PubMed] [Google Scholar]

58. Bickerstaff ER, Cloake PCP, Hughes B, Smith WT. The racemose form of cerebral cysticercosis. Brain. 1952;75:1–16. [PubMed] [Google Scholar]

59. Diwan AR, Coker-Vann M, Brown P, et al. Enzyme-linked immunosorbent assay (ELISA) for the detection of antibody to cysticerci of Taenia solium. Am J Trop Med Hyg. 1982;31:364–69. [PubMed] [Google Scholar]

60. Rosas N, Sotelo J, Nieto D. ELISA in the diagnosis of neurocysticercosis. Arch Neurol. 1986;43:353–56. [PubMed] [Google Scholar]

61. Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium) J Infect Dis. 1989;159:50–59. [PubMed] [Google Scholar]

62. Tsang VC, Pilcher JA, Zhou W, et al. Efficacy of the immunoblot assay for cysticercosis in pigs and modulated expression of distinct IgM/IgG activities to Taenia solium antigens in experimental infections. Vet Immunol Immunopathol. 1991;29:69–78. [PubMed] [Google Scholar]

63. Proano-Narvaez JV, Meza-Lucas A, Mata-Ruiz O, Garcia-Jeronimo RC, Correa D. Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. J Clin Microbiol. 2002;40:2115–18. [PMC free article] [PubMed] [Google Scholar]

64. Gekeler F, Eichenlaub S, Mendoza EG, Sotelo J, Hoelscher M, Loscher T. Sensitivity and specificity of ELISA and immunoblot for diagnosing neurocysticercosis. Eur J Clin Microbiol Infect Dis. 2002;21:227–29. [PubMed] [Google Scholar]

65. Wilson M, Bryan RT, Fried JA, et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis. 1991;164:1007–09. [PubMed] [Google Scholar]

66. Garcia HH, Gilman RH, Catacora M, Verastegui M, Gonzalez AE, Tsang VC. Serologic evolution of neurocysticercosis patients after antiparasitic therapy. J Infect Dis. 1997;175:486–89. [PMC free article] [PubMed] [Google Scholar]

67. Estrada JJ, Kuhn RE. Immunochemical detection of antigens of larval Taenia solium and antilarval antibodies in the cerebrospinal fluid of patients with neurocysticercosis. J Neurol Sci. 1985;71:39–48. [PubMed] [Google Scholar]

68. Correa D, Sandoval MA, Harrison LJ, et al. Human neurocysticercosis: comparison of enzyme immunoassay capture techniques based on monoclonal and polyclonal antibodies for the detection of parasite products in cerebrospinal fluid. Trans R Soc Trop Med Hyg. 1989;83:814–16. [PubMed] [Google Scholar]

69. Garcia HH, Harrison LJ, Parkhouse RM, et al. A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis. Trans R Soc Trop Med Hyg. 1998;92:411–14. [PMC free article] [PubMed] [Google Scholar]

70. Garcia HH, Parkhouse RM, Gilman RH, et al. Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients. Trans R Soc Trop Med Hyg. 2000;94:673–76. [PubMed] [Google Scholar]

71. Garcia HH, Herrera G, Gilman RH, et al. Discrepancies between cerebral computed tomography and western blot in the diagnosis of neurocysticercosis. Am J Trop Med Hyg. 1994;50:152–57. [PubMed] [Google Scholar]

72. Vasconcelos D. From cyst to cysticercus granuloma using cranial computerized tomography. Gac Med Mex. 1990;126:401–04. [PubMed] [Google Scholar]

73. Sheth TN, Pillon L, Keystone J, Kucharczyk W. Persistent MR contrast enhancement of calcified neurocysticercosis lesions. AJNR Am J Neuroradiol. 1998;19:79–82. [PMC free article] [PubMed] [Google Scholar]

74. Nash TE, Patronas NJ. Edema associated with calcified lesions in neurocysticercosis. Neurology. 1999;53:777–81. [PubMed] [Google Scholar]

75. Nash TE, Pretell J, Garcia HH. Calcified cysticerci provoke perilesional edema and seizures. Clin Infect Dis. 2001;33:1649–53. [PubMed] [Google Scholar]

76. Gupta RK, Kumar R, Chawla S, Pradhan S. Demonstration of scolex within calcified cysticercus cyst: its possible role in the pathogenesis of perilesional edema. Epilepsia. 2002;43:1502–08. [PubMed] [Google Scholar]

77. Martinez HR, Rangel-Guerra R, Elizondo G, et al. MR imaging in neurocysticercosis: a study of 56 cases. AJNR Am J Neuroradiol. 1989;10:1011–19. [PMC free article] [PubMed] [Google Scholar]

78. Del Brutto OH, Rajshekhar V, White AC, Jr, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001;57:177–83. [PMC free article] [PubMed] [Google Scholar]

79. Kramer LD, Locke GE, Byrd SE, Daryabagi J. Cerebral cysticercosis: documentation of natural history with CT. Radiology. 1989;171:459–62. [PubMed] [Google Scholar]

80. Cuetter AC, Garcia-Bobadilla J, Guerra LG, Martinez FM, Kaim B. Neurocysticercosis: focus on intraventricular disease. Clin Infect Dis. 1997;24:157–64. [PubMed] [Google Scholar]

81. Kelley R, Duong DH, Locke GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery. 2002;50:757–61. [PubMed] [Google Scholar]

82. Robles C, Chavarria Chavarria M. Report of a clinical case of cerebral cysticercosis treated medically with a new drug: praziquantel. Salud Publica Mex. 1979;21:603–18. [PubMed] [Google Scholar]

83. Botero D, Castano S. Treatment of cysticercosis with praziquantel in Colombia. Am J Trop Med Hyg. 1982;31:811–21. [PubMed] [Google Scholar]

84. Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med. 1984;310:1001–07. [PubMed] [Google Scholar]

85. Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for neurocysticercosis. Arch Intern Med. 1987;147:738–41. [PubMed] [Google Scholar]

86. Sotelo J, Escobedo F, Penagos P. Albendazole vs praziquantel for therapy for neurocysticercosis: a controlled trial. Arch Neurol. 1988;45:532–34. [PubMed] [Google Scholar]

87. Moodley M, Moosa A. Treatment of neurocysticercosis: is praziquantel the new hope? Lancet. 1989;1:262–63. [PubMed] [Google Scholar]

88. Kramer LD. Medical treatment of cysticercosis–ineffective. Arch Neurol. 1995;52:101–02. [PubMed] [Google Scholar]

89. Del Brutto OH. Medical treatment of cysticercosis–effective. Arch Neurol. 1995;52:102–04. [PubMed] [Google Scholar]

90. Carpio A, Santillan F, Leon P, Flores C, Hauser WA. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med. 1995;155:1982–88. [PubMed] [Google Scholar]

91. Baranwal AK, Singhi PD, Khandelwal N, Singhi SC. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. Pediatr Infect Dis J. 1998;17:696–700. [PubMed] [Google Scholar]

92. Baranwal AK, Singhi PD, Singhi SC, Khandelwal N. Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up. J Child Neurol. 2001;16:443–45. [PubMed] [Google Scholar]

93. Padma MV, Behari M, Misra NK, Ahuja GK. Albendazole in single CT ring lesions in epilepsy. Neurology. 1994;44:1344–46. [PubMed] [Google Scholar]

94. Padma MV, Behari M, Misra NK, Ahuja GK. Albendazole in neurocysticercosis. Natl Med J India. 1995;8:255–58. [PubMed] [Google Scholar]

95. Salinas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm infection of the brain) (Cochrane Review) Cochrane Database Syst Rev. 2003;2 CD000215. [PubMed] [Google Scholar]

96. Sotelo J, del Brutto OH, Penagos P, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol. 1990;237:69–72. [PubMed] [Google Scholar]

97. Corona T, Lugo R, Medina R, Sotelo J. Single-day praziquantel therapy for neurocysticercosis. N Engl J Med. 1996;334:125. [PubMed] [Google Scholar]

98. Pretell EJ, Garcia HH, Gilman RH, Saavedra H, Martinez M, Cysticercosis Working Group in Peru Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg. 2001;103:175–77. [PubMed] [Google Scholar]

99. Garcia HH, Evans CAW, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15:74–56. [PMC free article] [PubMed] [Google Scholar]

100. Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology. 1994;44:1706–09. [PubMed] [Google Scholar]

101. Gonzales AE, Garcia HH, Gilman RH, et al. Effective, single-dose treatment or porcine cysticercosis with oxfendazole. Am J Trop Med Hyg. 1996;54:391–94. [PubMed] [Google Scholar]

102. Gonzalez AE, Falcon N, Gavidia C, et al. Treatment of porcine cysticercosis with oxfendazole: a dose-response trial. Vet Rec. 1997;141:420–22. [PubMed] [Google Scholar]

103. Gonzalez AE, Falcon N, Gavidia C, et al. Time-response curve of oxfendazole in the treatment of swine cysticercosis. Am J Trop Med Hyg. 1998;59:832–36. [PubMed] [Google Scholar]

104. Lightowlers MW, Flisser A, Gauci CG, Heath DD, Jensen O, Rolfe R. Vaccination against cysticercosis and hydatid disease. Parasitol Today. 2000;16:191–96. [PubMed] [Google Scholar]

105. Verastegui M, Gilman RH, Gonzalez AE, et al. Taenia solium oncosphere antigen induces immunity in pigs against experimental cysticercosis. Vet Parasitol. 2002;108:49–62. [PubMed] [Google Scholar]

106. Gauci CG, Flisser A, Lightowlers MW. A Taenia solium oncosphere protein analogous to host-protective Taenia ovis and Taenia saginata 18kDa antigens. Int J Parasitol. 1998;28:757–60. [PubMed] [Google Scholar]

107. Plancarte A, Flisser A, Gauci CG, Lightowlers MW. Vaccination against Taenia solium cysticercosis in pigs using native and recombinant oncosphere antigens. Int J Parasitol. 1999;29:643–47. [PubMed] [Google Scholar]

108. Schantz PM, Sarti E, Plancarte A, et al. Community-based epidemiological investigations of cysticercosis due to Taenia solium: comparison of serological screening tests and clinical findings in two populations in Mexico. Clin Infect Dis. 1994;18:879–85. [PubMed] [Google Scholar]

109. Cruz ME, Schantz PM, Cruz I, et al. Epilepsy and neurocysticercosis in an Andean community. Int J Epidemiol. 1999;28:799–803. [PubMed] [Google Scholar]

110. Garcia-Noval J, Moreno E, de Mata F, et al. An epidemiological study of epilepsy and epileptic seizures in two rural Guatemalan communities. Ann Trop Med Parasitol. 2001;95:167–75. [PubMed] [Google Scholar]

111. Sanchez AL, Lindback J, Schantz PM, et al. A population-based, case-control study of Taenia solium taeniasis and cysticercosis. Ann Trop Med Parasitol. 1999;93:247–58. [PubMed] [Google Scholar]

112. Garcia HH, Gonzalez AE, Gilman RH, et al. Short report: transient antibody response in Taenia solium infection in field conditions–a major contributor to high seroprevalence. Am J Trop Med Hyg. 2001;65:31–32. [PubMed] [Google Scholar]

113. Verastegui M, Gonzalez A, Gilman RH, et al. Experimental infection model for Taenia solium cysticercosis in swine. Vet Parasitol. 2000;94:33–44. [PubMed] [Google Scholar]

114. Singh G. Neurocysticercosos in South-Central America and the Indian subcontinent: a comparative evaluation. Arq Neuropsiquiatr. 1997;55:349–56. [PubMed] [Google Scholar]

115. Cruz M, Davis A, Dixon H, Pawlowski ZS, Proano J. Operational studies on the control of Taenia solium taeniasis/cysticercosis in Ecuador. Bull World Health Organ. 1989;67:401–07. [PMC free article] [PubMed] [Google Scholar]

116. Garcia-Noval J, Allan JC, Fletes C, et al. Epidemiology of Taenia solium taeniasis and cysticercosis in two rural Guatemalan communities. Am J Trop Med Hyg. 1996;55:282–89. [PubMed] [Google Scholar]

117. Gonzalez AE, Cama V, Gilman RH, et al. Prevalence and comparison of serologic assays, necropsy, and tongue examination for the diagnosis of porcine cysticercosis in Peru. Am J Trop Med Hyg. 1990;43:194–99. [PubMed] [Google Scholar]

118. The Cysticercosis Working Group in Peru The marketing of cysticercotic pigs in the Sierra of Peru. Bull World Health Organ. 1993;71:223–28. [PMC free article] [PubMed] [Google Scholar]

119. Garcia HH, Gilman RH, Gonzalez AE, Pacheco R, Verastegui M, Tsang VC. Human and porcine Taenia solium infection in a village in the highlands of Cusco, Peru. Acta Trop. 1999;73:31–36. [PubMed] [Google Scholar]

120. Nicoletti A, Bartoloni A, Reggio A, et al. Epilepsy, cysticercosis, and toxocariasis: a population-based case-control study in rural Bolivia. Neurology. 2002;58:1256–61. [PubMed] [Google Scholar]

121. Placencia M, Sander JW, Shorvon SD, Ellison RH, Cascante SM. Validation of a screening questionnaire for the detection of epileptic seizures in epidemiological studies. Brain. 1992;115:783–94. [PubMed] [Google Scholar]

122. Jimenez I, Mora O, Uribe CS, et al. Factores de riesgo en epilepsia: estudio epidemiologico de cass y controles. Acta Medica Colombiana. 1991;16:5–14. [Google Scholar]

123. Osuntokun BO, Schoenberg BS. Research protocol for measuring the prevalence of neurological disorders in developing countries: results of a pilot study in Nigeria. Neuroepidemiology. 1982;1:143–53. [Google Scholar]

124. Naidoo DV, Pammenter MD, Moosa A, van Dellen JR, Cosnett JE. Seventy black epileptics: cysticercosis, computed tomography and electro-encephalography. S Afr Med J. 1987;72:837–88. [PubMed] [Google Scholar]

125. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. Lancet. 1993;341:197–200. [PMC free article] [PubMed] [Google Scholar]

126. Flisser A. Neurocysticercosis in Mexico. Parasitol Today. 1988;4:131–37. [PubMed] [Google Scholar]

127. Medina MT, Rosas E, Rubio-Donnadieu F, Sotelo J. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med. 1990;150:325–27. [PubMed] [Google Scholar]

128. Garcia HH, Gilman RH, Tsang VC, Gonzalez AE. Clinical significance of neurocysticercosis in endemic villages. Trans R Soc Trop Med Hyg. 1997;91:176–78. [PubMed] [Google Scholar]

129. Ong S, Talan DA, Moran GJ, et al. Neurocysticercosis in radiographically imaged seizure patients in US emergency departments. Emerg Infect Dis. 2002;8:608–13. [PMC free article] [PubMed] [Google Scholar]

130. Dietrichs E, Tyssvang T, Aanonsen NO, Bakke SJ. Cerebral cysticercosis in Norway. Acta Neurol Scand. 1993;88:296–98. [PubMed] [Google Scholar]

131. Roman G, Sotelo J, Del Brutto O, et al. A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ. 2000;78:399–406. [PMC free article] [PubMed] [Google Scholar]

132. Acevedo A. Economic impact of porcine cysticercosis. In: Flisser A, Willms K, Laclette JP, Larralde C, Ridaura C, Beltran F, editors. Cysticercosis: present state of knowledge and perspectives. Academic Press; New York: 1982. pp. 63–68. [Google Scholar]

133. Murrell KD. Economic losses resulting from food-borne parasitic zoonoses. Southeast Asian J Trop Med Public Health. 1991;22(suppl):377–81. [PubMed] [Google Scholar]

134. Bern C, Garcia HH, Evans C, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis. 1999;29:1203–09. [PMC free article] [PubMed] [Google Scholar]

135. Gilman R, Garcia HH, Gonzalez AE, et al. Short cuts to development: methods to control the transmission of cysticercosis in developing countries. In: Garcia HH, Martinez SM, editors. Taenia solium taeniasis/cysticercosis. 2nd edn. Ed Universo; Lima: 1999. pp. 313–26. [Google Scholar]

136. Schantz PM, Cruz M, Sarti E, Pawlowski Z. Potential eradicability of taeniasis and cysticercosis. Bull Pan Am Health Organ. 1993;27:397–403. [PubMed] [Google Scholar]

137. Allan JC, Velasquez-Tohom M, Fletes C, et al. Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs. Trans R Soc Trop Med Hyg. 1997;91:595–98. [PubMed] [Google Scholar]

138. Sarti E, Flisser A, Schantz PM, et al. Development and evaluation of a health education intervention against Taenia solium in a rural community in Mexico. Am J Trop Med Hyg. 1997;56:127–32. [PubMed] [Google Scholar]

139. Sarti E, Schantz PM, Avila G, Ambrosio J, Medina-Santillan R, Flisser A. Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg. 2000;94:85–89. [PubMed] [Google Scholar]

140. Gonzalez AE, Gavidia C, Falcon N, et al. Protection of pigs with cysticercosis from further infections after treatment with oxfendazole. Am J Trop Med Hyg. 2001;65:15–18. [PubMed] [Google Scholar]

141. Huerta M, de Aluja AS, Fragoso G, et al. Synthetic peptide vaccine against Taenia solium pig cysticercosis: successful vaccination in a controlled field trial in rural Mexico. Vaccine. 2001;20:262–66. [PubMed] [Google Scholar]

142. Lightowlers MW, Gauci CG. Vaccines against cysticercosis and hydatidosis. Vet Parasitol. 2001;101:337–52. [PubMed] [Google Scholar]

143. World Health Organization (WHO). Assembling a framework for intensified control of taeniasis and neurocysticercosis caused by Taenia solium: Report of an informal consultation. World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland; 2015.

144. FAO and WHO. Multicriteria-based ranking for risk management of food-borne parasites. Rome: Italy; 2014.

145. Murrell K, Dorny P, Flisser A, Geerts S, Kyvsgaard N, McManus D, et al., editors. WHO/FAO/OIE Guidelines for the surveillance, prevention and control of taeniosis/cysticercosis. Paris: World Health Organisation for animal health (OIE), 2005. OIE, 12, rue de Prony, 75017 Paris, France; 2005.

146. Okello A, Thomas L. Human taeniasis: Current insights into prevention and management strategies in endemic countries. Risk manag healthc policy. 2017;10:107–16.

147. Mwanjali G, Kihamia C, Kakoko DVC, Lekule F, Ngowi H, Johansen MV, et al. Prevalence and risk factors associated with human Taenia Solium infections in Mbozi District, Mbeya Region, Tanzania. PLoS Negl Trop Dis. 2013;7(3):e2102.

148. Ngowi HA, Carabin H, Kassuku AA, Mlozi MRS, Mlangwa JED, Willingham AL. A health-education intervention trial to reduce porcine cysticercosis in Mbulu District Tanzania. Prev Vet Med. 2008;85(1-2):52-67.

149. Gabriël S, Dorny P, Mwape KE, Trevisan C, Braae UC, Magnussen P, et al. Control of Taenia solium taeniasis/cysticercosis: the best way forward for sub-Saharan Africa? Acta Trop. 2017;165:252-60.

150. Braae UC, Saarnak CFL, Mukaratirwa S, Devleesschauwer B, Magnussen P, Johansen MV. Taenia solium taeniosis/cysticercosis and the co-distribution with schistosomiasis in Africa. Parasit Vectors. 2015;8(1):1–14.

151. Komba EVG, Kimbi EC, Ngowi HA, Kimera SI, Mlangwa JE, Lekule FP, et al. Prevalence of porcine cysticercosis and associated risk factors in smallholder pig production systems in Mbeya region, southern highlands of Tanzania. Vet Parasitol. 2013;198(3-4):284-91.

152. Kavishe MDB, Mkupasi EM, Komba EVG, Ngowi HA. Prevalence and risk factors associated with porcine cysticercosis transmission in Babati district, Tanzania. Livest Res Rural Dev. 2017;29(1):13.

153. Hunter E, Burton K, Iqbal A, Birchall D, Jackson M, Rogathe J, et al. Cysticercosis and epilepsy in rural Tanzania: a community-based case-control and imaging study. Trop Med Int Heal. 2015;20(9):1171–9.

154. Winkler AS, Willingham AL, Sikasunge CS, Schmutzhard E. Epilepsy and neurocysticercosis in sub-Saharan Africa. Wien Klin Wochenschr. 2009;121(SUPPL. 3):3-12.

155. Winkler AS. Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management. Pathog Glob Health. 2012;106(5):261-74.

156. Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, et al. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis. 2010;4(11):e870.

157. Trevisan C, Devleesschauwer B, Schmidt V, Winkler AS, Harrison W, Johansen MV. The societal cost of Taenia solium cysticercosis in Tanzania. Acta Trop. 2017;165:141–54.

158. World Health Organization WHO. A guide to developing knowledge, attitude and practice surveys. Geneva: World Health Organization; 2008.

159. Chacha M, Yohana C, Nkwengulila G. Indigenous knowledge, practices, beliefs and social impacts of porcine cysticercosis and epilepsy in Iringa Rural. Int J Infect Dis. 2014;178:2894.

160. Mwidunda S, Carabin H, Matuja W, Winkler A, Ngowi H. A school based cluster randomised health education intervention trial for improving knowledge and attitudes related to Taenia solium cysticercosis and taeniasis in Mbulu district, northern Tanzania. PLoS onE. 2015;10(2):1-17.

161. Ngowi HA, Mkupasi EM, Lekule FP, Willingham IL, Thamsborg SM. Impact of farmer education on their knowledge, attitudes, and practices in southern Tanzania: a case for Taenia solium control. Impact of farmer education on their knowledge, attitudes, and pr. Livest Res Rural Dev. 2011;23(1):1-8.

162. Ngowi HA, Mlangwa JED, Mlozi MRS, Tolma EL, Kassuku AA, Carabin H, et al. Implementation and evaluation of a health-promotion strategy for control of Taenia solium infections in northern Tanzania. Int J Heal Promot Educ. 2009;47(1):24–34.

163. Ertel RL, Braae UC, Ngowi HA, Johansen MV. Assessment of a computer-based Taenia solium health education tool ‘The Vicious Worm’ on knowledge uptake among professionals and their attitudes towards the program. Acta Trop. 2015;6:240–5.

164. Mwang’onde BJ, Nkwengulila G, Chacha M. The risk factors for human cysticercosis in Mbulu District Tanzania. onderstepoort J Vet Res. 2014;81(2):1–5.

165. Mwang’onde BJ, Chacha MJ, Nkwengulila G. The status and health burden of neurocysticercosis in Mbulu district, northern Tanzania. BMC Res Notes. 2018;11(1):1–5.

166. Ngowi HA, Kassuku AA, Maeda GEM, Boa ME, Carabin H, Willingham AL. Risk factors for the prevalence of porcine cysticercosis in Mbulu District Tanzania. Vet Parasitol. 2004;120(4):275–83.

166. Shonyela SM, Mkupasi EM, Sikalizyo SC, Kabemba EM, Ngowi HA, Phiri I. An epidemiological survey of porcine cysticercosis in Nyasa District, Ruvuma Region. Tanzania Parasite Epidemiol Control. 2017;2(4):35–41.

167. Boa ME, Mahundi EA, Kassuku AA, Willingham AL, Kyvsgaard NC. Epidemiological survey of swine cysticercosis using ante-mortem and post-mortem examination tests in the southern highlands of Tanzania. Vet Parasitol. 2006;139(1–3):249–55.

168. Fisher AA, Laing JE, Stoeckel JE, Townsend J. Handbook for family planning operations research design. 2nd edn., New York, New York, USA. 1991; p. 43.

169. Humanitarian Response. Kobo Toolbox. Cambridge, MA, USA. 2015. https://www.kobotoolbox.org/

170. Ngowi HA, Tolma EL, Kassuku AA, Mlozi MRS, Mlangwa JED, Carabin H, et al. Using the PRECEDE model to plan a health promotion strategy for control of Taenia solium infections in northern Tanzania. Int J Heal Promot Educ. 2007;45(2):41–8.

171. Winkler AS, Blocher J, Auer H, Gotwald T, Matuja W, Schmutzhard E. Epilepsy and neurocysticercosis in rural Tanzania: An imaging study. Epilepsia. 2009;50(5):987–93.

172. Alexander AM, Mohan VR, Muliyil J, Dorny P, Rajshekhar V. Changes in knowledge and practices related to taeniasis/cysticercosis after health education in a south Indian community. Int Health. 2012;4(3):164-9.

174. Sarti E, Flisser A, Schantz PM, Gleizer M, Loya M, Plancarte A, et al. Development and evaluation of a health education intervention against Taenia solium in a rural community in Mexico. Am J Trop Med Hyg. 1997;56(2):127-32.

175. World Health Organisation WHO. Ending the neglect to attain the sustainable development goals: A road map for neglected tropical diseases: 2021-2030. Geneva: World Health Organisation; 2021.

176. Carabin H, Millogo A, Ngowi HA, Bauer C, Dermauw V, Koné AC, et al. Effectiveness of a community-based educational programme in reducing the cumulative incidence and prevalence of human Taenia solium cysticercosis in Burkina Faso in 2011-14 (EFECAB): A cluster-randomised controlled trial. Lancet Glob Health. 2018;6(4):e411–25.

177. Gabriël S, Mwape KE, Hobbs EC, Devleesschauwer B, Van Damme I, Zulu G, et al. Potential elimination of active Taenia solium transmission in Africa. New Engl J Med. 2020;383(4):1-3.